問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉士芃

Recruiting

List

143Cases

2020-11-30 - 2025-05-27

Phase III

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    Venetoclax

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

2020-12-01 - 2022-06-24

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2017-12-19 - 2025-07-15

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

  • Condition/Disease

    DIFFUSE LARGE B-CELL LYMPHOMA

  • Test Drug

    Polatuzumab vedotin

Participate Sites
6Sites

Recruiting5Sites

高志平
Taipei Veterans General Hospital

2016-08-01 - 2021-01-10

Phase III

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First)

  • Condition/Disease

    Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

  • Test Drug

    Quizartinib (AC220)

Participate Sites
6Sites

Recruiting3Sites

Terminated3Sites

柯博伸
Taipei Veterans General Hospital

2021-08-01 - 2029-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-03-25 - 2026-07-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2018-11-15 - 2025-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2017-07-18 - 2024-06-30

Phase III

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

  • Condition/Disease

    Acute Myeloid Leukemia with an IDH1 Mutation

  • Test Drug

    Ivosidenib (AG-120);Azacitidine

Participate Sites
8Sites

Recruiting6Sites

蕭惠樺
Kaohsiung Municipal Gangshan Hospital

未分科

2021-11-01 - 2030-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-09-01 - 2025-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 10 11 12 13 14 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB